We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

By LabMedica International staff writers
Posted on 22 Oct 2024
Print article
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated number of hip and knee arthroplasties is expected to quadruple within the next 10 to 20 years. PJI impacts over 2% of these patients and has become the leading cause of revision arthroplasty. Rapid and accurate diagnosis of PJI is crucial for ensuring that patients receive the most suitable surgical or antimicrobial treatment plan. Now, a state-of-the-art, high-accuracy point-of-care test is being developed to diagnose PJI in under five minutes.

InfectoTest GmbH (Berlin, Germany) is developing InfectoSynovia, a rapid and high-accuracy test designed to identify PJI in less than five minutes. This test employs an innovative electrochemical analysis technique that requires only a minimal sample of synovial fluid. InfectoSynovia aims to significantly decrease the diagnosis time to under five minutes while providing excellent sensitivity and specificity, using a sample as small as 50 microliters (µl) of synovial fluid.

With InfectoTest's unique electrochemical analysis approach, complemented by software that aids in the precise interpretation of results, InfectoSynovia will be capable of detecting low-grade and culture-negative infections. This groundbreaking technology aims to transform the diagnosis of PJI, addressing an escalating global demand as the prevalence of joint replacements increases with aging populations.

"Our InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection,” said Svetlana Karbysheva, MD, PhD., Managing Director of InfectoTest.

Related Links:
InfectoTest GmbH

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Hepatitis B Virus Test
HBs Ab – ELISA
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.